ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Metabolomics of cerebrospinal fluid following traumatic brain injury: Exploration of biomarkers for secondary injuries and severity.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electroacupuncture Prevents TBI-Induced Synaptic Loss by Inhibiting CaMKII/Drp1-Dependent Mitochondrial Fission.Biomolecules · 2026Article
- Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) constitutes a major global public health concern associated with substantial mortality and long-term disability, while its diagnostic approaches and underlying pathophysiological mechanisms remain to be fully elucidated. In this study, we conducted longitudinal metabolomic profiling of cerebrospinal fluid (CSF) from 23 TBI patients (9 mild, 14 severe) and 5 uninjured controls using high-resolution mass spectrometry. Comprehensive quantification of metabolites was performed at three critical post-injury time points (days 1, 3, and 7), revealing distinct temporal metabolic patterns. Our results demonstrated significant alterations in the CSF metabolome following TBI. Early-phase changes (day 1) predominantly involved energy-related metabolites, including sphingosine, glucose, and dl-lactate. More pronounced metabolic shifts were observed by day 3, characterized by marked variations in amino acids (l-glutamine, l-histidine) and medium-chain fatty acids (caprylic acid, octanoic acid), suggesting the transition from primary to secondary injury mechanisms. The day 7 profile revealed accumulation of repair-associated metabolites such as 2'-deoxyuridine 5'-monophosphate and 1,2-dihexadecanoyl-sn-glycerol, potentially indicative of processes occurring in the chronic phase, which may include both reparative mechanisms and ongoing pathology. Notably, we identified significant alterations in established biomarkers (trimethylamine N-oxide) and novel small peptides (e.g., Gly-His-Lys), with distinct metabolic signatures differentiating mild versus severe TBI cases. These findings delineate temporally dynamic and severity-dependent metabolic reprogramming in TBI, providing mechanistic insights into the progression from acute injury through secondary pathogenesis to chronic recovery phases. The identified metabolic signatures may serve as potential biomarkers for injury staging and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.